[US-헬스케어] 07/09 Wall St. Recap

Eli Lilly (LLY) continues to demonstrate robust momentum, driven primarily by the unprecedented commercial success of its GLP-1 receptor agonists. While the stock has experienced a significant 410% appreciation over the past five years, the market remains focused on the company’s long-term earnings growth potential.

Beyond its core obesity franchise, LLY is strategically diversifying its portfolio, notably through a $3.8 billion investment in the vaccine market. This move signals a proactive approach to securing future revenue streams and mitigating dependency on a single therapeutic area. Despite trading near record highs, the company’s aggressive R&D pipeline and expanding manufacturing capacity suggest that the valuation is supported by strong fundamental tailwinds rather than mere speculative sentiment. Investors should monitor the scalability of production to meet global demand, which remains the primary catalyst for sustained price appreciation.

Novo Nordisk (NVO) continues to demonstrate strong market momentum, recently bolstered by the UK regulatory approval of its oral formulation. This development is a critical milestone, as it expands the company’s therapeutic delivery options beyond injectable treatments, potentially capturing a broader patient demographic and enhancing long-term market penetration. While historical volatility remains a factor, the successful transition toward oral administration positions the firm to sustain its leadership in the GLP-1 market, providing a robust catalyst for growth heading into 2026.

Amgen (AMGN) is currently navigating a complex landscape defined by significant legal and regulatory volatility. The recent judicial intervention blocking Colorado’s price cap on the blockbuster drug Enbrel provides a critical short-term victory for the company’s pricing power and sets a favorable precedent against state-level pharmaceutical price controls.

However, this is offset by mounting litigation risks regarding patent infringement and the reputational damage stemming from the retraction of clinical trial data for Tavneos. Investors should remain cautious; while the legal win on pricing protects near-term revenue streams, the combination of patent exposure and clinical integrity concerns introduces significant uncertainty regarding the company’s long-term growth trajectory and R&D credibility.

UnitedHealth Group (UNH) is currently navigating a complex landscape defined by conflicting signals regarding its Medicare Advantage (MA) enrollment and valuation metrics. While recent reports indicate a potential contraction of 2 to 3 million members, which raises concerns regarding long-term institutional sentiment and market share, the sell-side remains optimistic. Analysts from firms like Morgan Stanley emphasize strong utilization trends as a primary driver for upward price target revisions. However, the stock faces a tug-of-war between its robust operational performance and concerns over overvaluation relative to historical multiples. Investors should monitor whether the company can maintain its margin expansion despite the headwinds in membership growth.

Pfizer (PFE) is currently navigating a period of significant operational volatility and leadership transition. The recent departure of the CFO, coupled with a disappointing outcome in a key drug trial, has exacerbated investor skepticism regarding the company’s long-term growth pipeline. While some analysts suggest the stock may be approaching a valuation floor following a sharp decline, the lack of immediate catalysts to offset the post-pandemic revenue cliff remains a primary concern. Investors should remain cautious until the company demonstrates a clearer path toward R&D efficiency and successful commercialization of its new product portfolio.